Overview
Supporting you in navigating the complex regulatory and access landscape
Join us for our 3rd Joint DIA-EUCOPE Workshop on ATMPs, Innovative Cell and Gene Therapies in the EU for the opportunity to collaborate and share expertise in a unique event where thought leaders will come together to partner and share collective intelligence on regulatory, evidence and access challenges for innovative Gene and Cell therapies.
Be informed by experts, join the discussion and be part of the solution
- Hear directly from regulators, payers, patient representatives, industry and academic organisations through interactive sessions, networking and open forums
- Take part and share your insights in the first global conference where key stakeholders will discuss how the approval of the COVID-19 vaccine will influence the regulatory landscape for advanced therapies
- Ignite conversation, collaboration and change in how we improve access to innovative treatments by accelerating their way to the market and ultimately to patients
- Gain practical knowledge on how to best navigate the complex access landscape of the advanced therapies
Flexible format with interactive sessions
- This workshop consists of two half-days, in the afternoon CET, so you can better adapt your schedule and attend in parallel to your regular job
- Networking sessions, combined with a bespoke forum tool will give you the possibility to take the discussion further and drive transformational outcomes
Program Committee
-
Ania Mitan Senior Vice President & Managing Director, DIA EMEA and India
DIA, Switzerland -
Paolo Morgese, MSc Head of Public Affairs
Alliance for Regenerative Medicine (ARM), Belgium -
Sam Ringle, PhD EU Regulatory Affairs Manager
CSL Behring Innovation Gmbh, Germany -
Martin Telko, PhD, MS Global Public Affairs Director for Biomedical Innovation
Novartis, Switzerland -
Sara Torgal, MPharm Senior Manager, Scientific Programs
DIA, Switzerland -
Maren von Fritschen, PharmD Head EU Regulatory Policy
Moderna, Netherlands -
Keith Wonnacott, PhD Vice President, Regulatory Affairs
Lexeo Therapeutics, United States
Have an account?